

WYDUR Board Meeting Minutes
Thursday, November 30, 2006
Casper, Wyoming
11 a.m. – 3 p.m.

Members present: Michael Carpenter, Bill Harrison, Kurt Hopfensperger, Richard Johnson, Bill Keenan, Dean Wunsch, Antoinette Brown, Donna Artery

Excused: Roxanne Brown, Steve Brown, Becky Drnas

By teleconference: Scott Johnston, Kevin Robinett, Aimee Lewis, Deb Devereaux, Kendra Grande, Linda Martin

Guests: John Stockton, Genentech, Inc.; Tim Crilly, Sepracor; Gary Dent, UCB Pharmaceuticals; Lori Howarth, Berlex, Inc.; Carmen Pyper, Pfizer; Kristin George, Pfizer; James Gaustad, Purdue; Johnna Nelson, Lilly; Tim Hynek, Lilly

Dr. Harrison called the meeting to order at 11:05.

Minutes of July 2006

The minutes of the September 28, 2006 meeting were approved as presented.

Department of Health

1. Approval and Denial statistics (handout). The Department is working on a compliance rate for the Preferred Drug List.
2. Smoking Cessation product coverage: APS will work with the Department/DUR on education. Implementation of product coverage will be January 1, 2007.
3. Discussed non-sedating antihistamines and potential for interaction between Singulair and loratadine. Linda Martin will do additional research and bring more information to the January 2007 meeting.

Old Business

Anti-epileptic criteria: Discussion of letter from State Hospital physicians. The Board does not feel that the response warrants changes in the criteria. Criteria were approved as presented. The Board will deal with exceptions on a case by case basis.

ADHD and PPI criteria updates were tabled until the January 2007 meeting.

Mental Health Project: There is no specific evidence supporting the use of multiple anti-psychotic agents concurrently. The Board recommended no changes to current policy, and will review again in six months.

Quetiapine utilization: Linda Martin reported on low-dose quetiapine utilization for insomnia. A very small number (2 – 3% of profiles reviewed) appear to be using quetiapine in this manner. Not likely to be an issue. Linda will provide a chart with her findings for January 2007 meeting.

APS Update: Deb Devereaux reported on pre-diabetes presentation by Dr. Wedell. There were ninety participants in the original presentation. Presentation will be

available by web cast at the end of December or first of January. APS/DUR will also be mailing educational letters to providers in three counties with materials from Lilly. Preliminary discussions regarding an educational program on ADHD were started following recommendations from the Preferred Drug List Advisory Committee. This program will be scheduled during 2007. The DUR Board recommended education in the schools as well as providers.

New Business

The Board discussed utilization of high dose ADHD medications. The major concern is side effects, however, limitations are difficult as these medications are dosed based on weight. The Board decided that this was a good opportunity for education through the DUR newsletter.

The Board discussed utilization of Zovirax ointment. The labeling states that Zovirax ointment should not be used unless the patient is immunocompromised. This issue was tabled until the January 2007 meeting pending additional information.

High dose Cymbalta was discussed. For Major Depression 60 mg is optimal, with little evidence for doses above 60 mg per day. Side effects increase above this level. Those with diabetic peripheral neuropathy may benefit from 90 to 120 mg per day. The Board recommended a newsletter article on the issue.

Other

A letter from Dr. Zondag concerning compounded fentanyl troches was discussed. Dr. Zondag requested that these troches be covered without limitations. The Board recommended that the Department continue with current policy.

A letter from Dr. Zondag concerning the potential for torsades de pointes with methadone was discussed. The Preferred Drug List Advisory Committee recently discussed this issue and recommended no change in preferred drugs; however, methadone should not be promoted as first line treatment and should only be prescribed by those with experience with the medication.

Dr. Johnston also received a letter from Dr. Johnston requesting that Kadian be made preferred. The Board recommended no changes as Kadian is another form of morphine sulfate which is currently a preferred agent.

Open Comments

No open comments were provided.

The Board met to review alert revisions, provider responses and patient profiles. There being no further business, the meeting was adjourned at 2:00 p.m.

Respectfully Submitted,

Aimee Lewis, PharmD
WYDUR Manager

Nov 30, 2006

May - August 2006 Approval/Denial Report

Zofran®

	<u>Approval</u>	<u>Denial</u>
Smart PA Report	20	236
ACS Monthly Report	45	7
State	2	0

ACE-Inhibitors

	<u>Approval</u>	<u>Denial</u>
Smart PA Report	28	63
ACS Monthly Report	18	2
State	1	3

Antihistamines

	<u>Approval</u>	<u>Denial</u>
Smart PA Report	208	860
ACS Monthly Report	178	46
State	14	6

Calcium Channel Blockers

	<u>Approval</u>	<u>Denial</u>
Smart PA Report	55	295
ACS Monthly Report	69	6
State	5	0

Long Acting Opiods

	<u>Approval</u>	<u>Denial</u>
Smart PA Report	166	645
ACS Monthly Report	84	38
State	7	7

NSAIDs

	<u>Approval</u>	<u>Denial</u>
Smart PA Report	278	649
ACS Monthly Report	178	21
State	7	5

Overactive Bladder Medications

	<u>Approval</u>	<u>Denial</u>
Smart PA Report	36	118
ACS Monthly Report	32	3
State	1	

Proton Pump Inhibitors

	<u>Approval</u>	<u>Denial</u>
Smart PA Report	352	625
ACS Monthly Report	238	10
State	5	1

Skeletal Muscle Relaxants

	<u>Approval</u>	<u>Denial</u>
Smart PA Report	357	526
ACS Monthly Report	216	6
State	1	

Statins

	<u>Approval</u>	<u>Denial</u>
Smart PA Report	0	389
ACS Monthly Report	11	13
State	1	1